Sample size re-estimation in an on-going NIH-sponsored clinical trial: The secondary prevention of small subcortical strokes experience

Contemporary Clinical Trials

Volumn 33, Issue 5, 2012, Pages 1088-1093

  McClure, Leslie A ^a   Szychowski, Jeff M ^a   Benavente, Oscar ^b   Coffey, Christopher S ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Randomized clinical trial; Sample size re estimation; SPS3

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; METHODOLOGY; RECURRENT DISEASE; SAMPLE SIZE; SECONDARY PREVENTION; STROKE; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; SECONDARY PREVENTION; STROKE; UNITED STATES;

EID: 84864295698     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2012.06.007     Document Type: Article

References (41)

1. Dragalin V. Adaptive designs: terminology and classification. Drug Inf J 2006, 40:425-435.
2. Chow S., Chang M. Adaptive design methods in clinical trials 2007, Chapman & Hall/CRC, Boca Raton.
3. Chow S.C., Chang M. Adaptive design methods in clinical trials - a review. Orphanet J Rare Dis 2008, 3:11.
4. Coffey C.S., Kairalla J.A. Adaptive clinical trials: progress and challenges. Drugs R&D 2008, 9:229-242.
5. Bretz F., Branson M., Burmann C.F., Chuang-Stein C., Coffey C.S. Adaptivity in drug discovery and development. Drug Dev Res 2009, 70:169-190.
6. Bretz F., Koenig F., Brannath W., Glimm E., Posch M. Adaptive designs for confirmatory clinical trials. Stat Med 2009, 28:1181-1217.
7. Gaydos B., Anderson K.B., Berry D., et al. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J 2009, 43:539-556.
8. Quinlan J., Gaydos B., Maca J., Krams M. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clin Trials 2010, 7:167-173.
9. Garrett-Mayer E. The continual reassessment method for dose-finding studies: a tutorial. Clin Trials 2006, 3:57-71.
10. Bornkamp B., Bretz F., Dmitrienko A., et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat 2007, 17:965-995.
11. Temple R. Enrichment of clinical study populations. Clin Pharmacol Ther 2010, 88:774-778.
12. Zhang L., Rosenburger W. Adaptive randomization in clinical trials. Design and analysis of experiments, special designs and applications 2012, vol. 3. John Wiley & Sons, Hoboken. K. Hinkelmann (Ed.).
13. Maca J., Bhattacharya S., Dragalin V., Gallo P., Krams M., et al. Adaptive seamless phase II/III designs: background operational aspects and examples. Drug Inf J 2006, 40:463-473.
14. Stallard N., Todd S. Seamless phase II/III designs. Stat Methods Med Res 2010, 20:623-634.
15. Wittes J., Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med 1990, 9:65-72.
16. Proschan M.A. Two-stage sample size re-estimation based on a nuisance parameter: a review. JBS 2005, 15:559-574.
17. Proschan M.A. Sample size re-estimation in clinical trials. Biom J 2009, 51:348-357.
18. Gallo P., Chuang-Stein C., Dragalin V., Gaydos B., Krams M., Pinheiro J. Adaptive designs in clinical drug development - an executive summary of the PhRMA working group. JBS 2009, 16:275-283.
19. Food and Drug Administration Guidance for industry: adaptive design clinical trials for drugs and biologics draft guidance Accessed at:. http://http:/www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
20. Bauer P., Kohne K. Evaluations of experiments with adaptive interim analyses. Biometrics 1994, 50:1029-1041.
21. Proschan M.A., Hunsberger S.A. Designed extension of studies based on conditional power. Biometrics 1995, 51:1315-1324.
22. Lehmacher W., Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999, 55:1286-1290.
23. Chi L., Hung H.M.J., Wang S.J. Modification of sample size in group sequential clinical trials. Biometrics 1999, 55:853-857.
24. Muller H.H., Schafer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and classical group sequential approaches. Biometrics 2001, 23:2497-2508.
25. Tsiatis A.A., Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003, 90:367-378.
26. Jennison C., Turnbull B.W. Mid-course sample size modification in clinical trials based on the observed treatment effect. Stat Med 2003, 22:971-993.
27. Jennison C., Turnbull B.W. Efficient group sequential designs when there are several effect sizes under consideration. Stat Med 2006, 25:917-932.
28. Friede T., Kieser M. Sample size recalculation in internal pilot study designs: a review. Biom J 2006, 48:537-555.
29. Proschan M.A. Sample size re-estimation in clinical trials. Biometrics J 2009, 51:348-357.
30. Benavente O.R., White C.L., Pearce L., Pergola P., Roldan A., Benavente M.F., et al. The Secondary Prevention of Small Subcortical Stroke (SPS3) study. Int J Stroke 2011, 6:164-175.
31. Mohr J.F., Thompson J.L.P., Lazar R.M., Levin B., Sacco R.L., Furie K.L., et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001, 345:1444-1451.
32. Jennison C., Turnbull B.W. Group sequential methods with applications to clinical trials 2000, Chapman & Hall/CRC, Boca Raton.
33. Schoenfeld D.A. Sample size formula for the proportional hazards regression model. Biometrics 1983, 39:499-503.
34. Birkett M.A., Day S.J. Internal pilot studies for estimating sample size. Stat Med 1994, 1994(13):15-30.
35. Morgan C.C. Sample size re-estimation in group-sequential response-adaptive clinical trials. Stat Med 2003, 22:3843-3857.
36. Mehta C.R., Tsiatis A.A. Flexible sample size considerations using information-based monitoring. Drug Inf J 2001, 35:1095-1112.
37. Kairalla J.A., Muller K.E., Coffey C.S. Combining internal pilots with an interim analysis for single degree of freedom tests. Commun Stat Theory Methods 2010, 39(20):3717-3738.
38. Cheung K., Kaufmann P. Efficiency perspectives on adaptive designs in stroke clinical trials. Stroke 2011, 42:2990-2994.
39. Amarenco P., Bogousslavsky J., Callahan A., Goldstein L.B., Hennerici M., Rudolph A.E., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549-559.
40. Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (esprit): randomised controlled trial. Lancet 2006, 367:1665-1673.
41. Sacco R.L., Diener H.C., Yusuf S., Cotton D., Ounpuu S., Lawton W.A., et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008, 359:1238-1251.